Cargando…

Alteration of HIV epitope processing and presentation by HIV protease inhibitors

Detalles Bibliográficos
Autores principales:	Kourjian, G, Boucau, J, Shimada, M, Lai, NY, Le Gall, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441341/ http://dx.doi.org/10.1186/1742-4690-9-S2-P275

Ejemplares similares

Mechanisms of HIV Protein Degradation into Epitopes: Implications for Vaccine Design
por: Rucevic, Marijana, et al.
Publicado: (2014)

Variable processing and presentation of HIV epitopes in dendritic cells and macrophages to CD8 T cells
por: Gourdain, P, et al.
Publicado: (2012)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
por: Boucau, J, et al.
Publicado: (2012)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Metabolic complications during HIV-treatment with protease inhibitors in patients from Braşov
por: Cocuz, Maria-Elena, et al.
Publicado: (2014)

Variable Processing and Cross-presentation of HIV by Dendritic Cells and Macrophages Shapes CTL Immunodominance and Immune Escape
por: Dinter, Jens, et al.
Publicado: (2015)

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

Targeting flexibility: a structure-based computational study revealing allosteric HIV-1 protease inhibitors
por: Kunze, Jens, et al.
Publicado: (2014)

RNA remarkably promotes HIV-1 protease fast turnover for NCp15 processing in mild acidic conditions leading to condensation of HIV-1 nucleocapsid
por: Lyonnais, Sebastien, et al.
Publicado: (2013)

A simple methodology to assess endolysosomal protease activity involved in antigen processing in human primary cells
por: Vaithilingam, Archana, et al.
Publicado: (2013)

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
por: Cingolani, A, et al.
Publicado: (2010)

Disturbance of HDL apolipoprotein AI metabolism in severe hyperlipidemic and lipodystrophic HIV patients on a protease inhibitor treatment
por: Ouguerram, Khadija, et al.
Publicado: (2010)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

A novel HIV vaccine targets the 12 protease cleavage sites
por: Luo, M, et al.
Publicado: (2012)

Molecular modelling studies of synthesized pentacyclo-undecane peptides as potential HIV-1 wild type C-SA protease inhibitors
por: Honarparvar, Bahareh, et al.
Publicado: (2013)

Implications of post-translational modifications of IRF7 on pDC IFN-alpha response
por: Griesbeck, M, et al.
Publicado: (2012)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

Assessment of T cell immune responses towards HIV-1 epitopes designed by reverse immunogenetic approach: proof-of-concept in HIV+ Cameroonian children
por: Nemes, E, et al.
Publicado: (2012)

P17-24. Interfering overlapping epitopes contribute to the subdominance of an HLA-A2-restricted HIV Gag-specific epitope
por: Kan-Mitchell, J, et al.
Publicado: (2009)

Naturally occurring protease inhibitor resistance mutations and their frequencies in HIV proviral sequences of drug-naïve sex workers in Nairobi, Kenya
por: Sampathkumar, Raghavan, et al.
Publicado: (2014)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1
por: Braibant, M, et al.
Publicado: (2012)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Study of changes in lipid profile and fasting blood glucose in protease inhibitor exposed HIV/AIDS patients in School of Tropical Medicine, Kolkata
por: Bhowmik, Ananya, et al.
Publicado: (2012)

Limited evidence for alterations in Gag-mediated HIV replication capacity over the course of the North American epidemic (1979-present)
por: Cotton, L, et al.
Publicado: (2012)

P17-28 LB. The antiviral efficacy of HIV-specific CD8+ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
por: Ranasinghe, S, et al.
Publicado: (2009)

Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses
por: Hulot, SL, et al.
Publicado: (2012)

Novel strategies for HIV-1 epitope delivery using foamy viral hybrid proteins and vectors
por: Mühle, M, et al.
Publicado: (2012)

Prevalence of drug resistance mutations in HIV-1 protease gene from North India
por: Azam, Mohd, et al.
Publicado: (2012)

Early presentation of HIV-1 KF11Gag and KK10Gag protective epitopes facilitate rapid CD8+ T cell activation and killing of virus infected cells
por: Kløverpris, HN, et al.
Publicado: (2012)

Comparison of cellular and humoral immune responses induced by primary, consensus or mosaic HIV-1 Env DNA vaccines
por: Yan, J, et al.
Publicado: (2012)

P05-09. 4e10 epitope-scaffolds mimic the antibody-bound epitope conformation and block neutralization by sera from rare HIV+ individuals
por: Ban, YA, et al.
Publicado: (2009)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

P16-39. T cell recognition of autologous and non-autologous HIV-1 protease peptides by HIV-1 infected patients undergoing PI therapy
por: Moraes, SL, et al.
Publicado: (2009)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2(nd) line antiretroviral regimen
por: Nouhin, Janin, et al.
Publicado: (2011)

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
por: Adamson, Catherine S.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_94o6d2vrknu8laiq5j84n5gh68